Key result
Low-dose prasugrel premedication significantly lowered the frequency of thromboembolic events compared to clopidogrel (0.9% vs 6.4%; P=0.01) without increasing hemorrhagic complications.
Why the study?
Does low-dose prasugrel compared to clopidogrel reduce thromboembolic events without increasing hemorrhage in patients undergoing stent-assisted coil embolization of unruptured intracranial aneurysms?
Cohort (n=297)
Does low-dose prasugrel compared to clopidogrel reduce thromboembolic events without increasing hemorrhage in patients undergoing stent-assisted coil embolization of unruptured intracranial aneurysms?
Absolute Event Rate: 0.9% vs 6.4%
p-value: p=0.01
Low-dose prasugrel premedication significantly reduces thromboembolic events compared to clopidogrel without increasing hemorrhagic risk in patients undergoing stent-assisted coil embolization of unruptured intracranial aneurysms.
No takes yet. Share an insight, caveat, or question.
Low-dose prasugrel may warrant prospective testing versus clopidogrel for aneurysm stenting; leaves open practice change pending randomized data.
Choi et al. (2017) conducted a cohort in Unruptured intracranial aneurysm (n=297). Low-dose prasugrel vs. Clopidogrel was evaluated on Thromboembolic events (p=0.01). Low-dose prasugrel premedication significantly lowered the frequency of thromboembolic events compared to clopidogrel (0.9% vs 6.4%; P=0.01) without increasing hemorrhagic complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: